when critically progressive dilatation of arch aneurysm was observed. Kaplan-Meier 1-year, 3-year, and 5-year survival rates were 84% 6 3%, 65% 6 5%, and 50% 6 6%, respectively.
Objectives: Mesh-covered carotid stents have been recently developed to reduce carotid artery stenting (CAS) intraprocedural cerebral embolization and prevent postprocedural adverse neurologic events related to the atherosclerotic plaque protrusion that occurred with prior-generation carotid stents. The aim of the present study was to evaluate periprocedural and 30-day outcomes in a prospective series of patients treated with the CGuard embolic prevention stent system (EPS).
Methods: From April 2015 to June 2016, a physician-initiated prospective multicenter study was performed in consecutive patients admitted to protected CAS and treated using CGuard EPS in 12 vascular centers. Outcome measures were technical success, perioperative (0-24 hours) and postoperative (24 hours-30 days) major and minor stroke, death, acute myocardial infarction (AMI), transient ischemic attack (TIA), and external carotid occlusion. In addition, in three centers with feasibility of routine diffusion-weighted magnetic resonance cerebral imaging (DW-MRI), consecutive study patient DW-MRI was performed #72 hours before the intervention and after #72 hours.
Results: Target sample recruitment of 200 patients was reached per protocol. Distal embolic protection device was used in 182 patients, and a MoMa system was used in 18 patients (9%). An independent committee reviewed the events. Technical success was 100%; one patient required two stents to cover the entire lesion length. No death, AMI, or major stroke occurred perioperatively, but there were four periprocedural minor strokes (2%). In addition, there were 2 TIAs, 2 transient mental confusions, and 2 hemodynamic instabilities. At the 30-day follow-up, one stent was explanted due to partial thrombosis and clinical minor stroke (0.5%) in a patient who did not adhere to any antiplatelet drug postdischarge, and one other stent (that was nonoptimized at the index procedure due to hemodynamic instability) required postdilatation. In the remaining patients (198 of 200 [99%] ), 1-month follow-up duplex ultrasound imaging revealed optimal technical result, and the clinical follow-up was uneventful. No external carotid artery occlusion occurred. In DW-MRI centers, 61 of 64 consecutive patients were evaluated per protocol (MRI contraindications prohibited imaging in 3). New postoperative DW-MRI lesions were detected in 12 patients (19.6%); six had contralateral-only and six had bilateral lesions.
Conclusions: Real-world use of the CGuard EPS was associated with no major neurologic complications by 30 days. The system showed effective postprocedural protection against adverse neurologic events during stent healing.
Author Disclosures: L. Capoccia: Nothing to disclose; R. Casana: Nothing to disclose; W. Mansour: Nothing to disclose; C. Pranteda: Nothing to disclose; C. Setacci: Nothing to disclose; P. Sirignano: Nothing to disclose; F. Speziale: Nothing to disclose. Objectives: The purpose of this study was to investigate the impact of aortic remodeling and true lumen expansion after proximal thoracic stent grafting and distal bare stenting in patients with chronic complicated type B aortic dissection.
IF15.

Implantation of Proximal
Methods: From June 2011 to December 2016, 67 patients received stainless steel-base thoracic stent graft implantation for chronic complicated type B aortic dissection. Of these, 30 only received proximal thoracic stent Significant within-group difference with 3-month postoperative data. c P < .05.
graft implantation (no bare-stent group), and 37 of them received proximal thoracic stent graft and distal bare-stent implantation (bare-stent group). All patients received computed tomography with contrast injection for evaluation preoperatively and at 3, 6, and 12 months postoperatively. The area of true and false lumen was measured at the pulmonary artery level of aorta, diaphragm level of aorta, renal artery level of aorta, middle infrarenal aorta, and distal aorta bifurcation, and the true lumen ratio was calculated accordingly.
Results: In the no bare-stent group, 5 patients presented with total regression of the false lumen extending from the thoracic to abdominal aorta, 9 with partial regression with total thrombosis of false lumen, and 16 with a patent false lumen. In the bare-stent group, 9 presented with total regression, 7 with partial regression, and 21 with a patent false lumen. There was no significant difference between two groups for any types of aortic remodeling (P ¼ .552 in total regression, P ¼ .390 in partial regression, P ¼ .809 in patent false lumen). The postoperative true lumen area ratio significantly increased in both groups (P < .05). When comparing the degree of postoperative true lumen expansion between the two groups, the true lumen expansion was significantly bigger in bare-stent group than in no bare-stent group at all five levels of the aorta (P < .001).
Conclusions: Proximal thoracic stent grafting for coverage of major thoracic dissection inlets with distal bare stenting effectively expands thoracic and abdominal aorta true lumen area but does not promote aortic remodeling in patients with chronic complicated type B aortic dissection.
Author Disclosures: I. Chen: Nothing to disclose; P. Chen: Nothing to disclose; C. Huang: Nothing to disclose; C. Shih: Nothing to disclose. Fig 1) , hybrid repair (H group) in 10 (34.5%; Fig 2) , and endovascular custom-made fenestrated endograft (E group) in 5 (17.2%). Outcomes are reported according to the Society for Vascular Surgery/AASS standards. Patients were evaluated with computed tomography scans in the outpatient clinic at 3, 6, and 12 months and then annually if not otherwise required.
IF16.
Management of Recurrent
Results: Results are summarized in Table III . Technical success (24 hours) was achieved in all cases with a median procedural time of 250 minutes (O: 220 minutes; H: 255 minutes; E: 320 minutes) and median intraoperative estimated blood loss of 1000 mL (O: 1475 mL; H: 550 mL; E: 400 mL). The 30-day mortality was 13.8% (O: 14.3%; H: 20%; E: 0%). 
